Wave Life Sciences director proposes $42.5K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Wave Life Sciences Ltd. director Heidi L. Wagner reported a proposed sale of 7,000 common shares, with an aggregate market value of $42,490.00 and an approximate sale date of August 11, 2026. The shares were acquired that day through an exercise of stock options from the issuer, with cash payment. March 6, 2026 is listed as the plan adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.